Dezhan Healthcare Company Limited (000813.SZ) Bundle
Founded in 1999, Dezhan Healthcare Company Limited (000813.SZ) has evolved into a cardiovascular and cerebrovascular specialist whose 2023 operating revenue reached ¥1.08 billion, a year‑over‑year rise of 12.3%, while diversifying into medical devices and services and planning a Science and Technology Innovation Development Center (July 2025) to accelerate R&D-driven growth; the company's mission to deliver safe, affordable care is reflected in a 92% customer satisfaction rating in 2023 and measurable sustainability gains-reported reductions include 5% lower carbon emissions in 2023 alongside initiatives that achieved a 40% drop in waste generation and a 20% decrease in carbon footprint, while operational improvements boosted project response times by 35% and employee engagement by 15%, all underscoring Dezhan's vision to scale global impact through innovation, integrity, and customer commitment.
Dezhan Healthcare Company Limited (000813.SZ) - Intro
Overview- Founded in 1999, Dezhan Healthcare Company Limited (000813.SZ) specializes in the research, development, manufacturing and sale of cardiovascular and cerebrovascular drugs across mainland China.
- Core therapeutic focus: lipid-lowering, antihypertensive, anti-anginal and antiarrhythmic medications marketed to hospitals, distributors and retail channels.
- Flagship and key products:
- Atorvastatin calcium tablets
- Amlodipine-atorvastatin combination tablets
- Trimetazidine hydrochloride capsules
- Amiodarone hydrochloride tablets
- Expanded offerings include medical devices and health-related services to diversify revenue streams and capture downstream care opportunities.
- To prevent and treat cardiovascular and cerebrovascular disease through accessible, high-quality medicines and integrated healthcare solutions that improve patient outcomes across China.
- To be a leading domestic innovator and trusted provider in cardiovascular and cerebrovascular care, leveraging R&D and technology to expand into comprehensive chronic-disease management.
- Patient-centered innovation: prioritize safety, efficacy and patient access.
- Scientific rigor: data-driven R&D and quality manufacturing.
- Integrity and compliance: adherence to regulatory and ethical standards.
- Sustainability and social responsibility: minimize environmental impact and contribute to public health.
| Metric | 2023 |
|---|---|
| Operating revenue | ¥1.08 billion |
| Year-over-year revenue growth | +12.3% |
| Reported carbon emissions reduction (vs prior year) | 5% reduction |
| Business segments | Cardiovascular & cerebrovascular pharmaceuticals, medical devices, health services |
- Strategic priority: convert clinical and formulation expertise into differentiated products and device-drug combinations to address unmet needs in cardiovascular care.
- July 2025 initiative: announced establishment of a Science and Technology Innovation Development Center to integrate internal and external expert resources, accelerate pipeline projects and enhance technological innovation.
- Expected outcomes: streamlined translational research, strengthened regulatory strategy, and faster time-to-market for next-generation therapies and devices.
- Product diversification: expand beyond small molecules into devices and integrated care solutions to capture higher-margin segments.
- R&D investment: focus on fixed-dose combinations, formulation optimization and lifecycle management of core drugs.
- Market expansion: strengthen hospital channel penetration and regional distributor networks across second- and third-tier cities.
- ESG and operational efficiency: continue emissions reduction programs and supply-chain sustainability to meet international environmental standards.
Dezhan Healthcare Company Limited (000813.SZ) - Overview
Dezhan Healthcare's mission centers on elevating public health standards through advanced technologies and customer-centric services. The company emphasizes safe, effective and affordable healthcare solutions designed to improve patient outcomes and build sustained relationships with customers, medical institutions and stakeholders. Dezhan pairs community engagement with measurable sustainability and innovation targets as integral components of corporate strategy.- Mission: Enhance public health standards via technology-driven, customer-focused healthcare solutions that are safe, effective and affordable.
- Patient impact: Prioritize products and services that demonstrably improve patient outcomes and accessibility.
- Stakeholder relations: Develop long-term partnerships with distributors, hospitals and community health initiatives.
- Research & Development: Dezhan reports a meaningful R&D allocation from capital expenditure, underscoring long-term innovation priorities.
- Sustainability: The company reported a 5% reduction in carbon emissions in 2023 versus 2022, reflecting operational efficiency and decarbonization efforts.
- Market expansion: New distribution agreements in Southeast Asia are expected to expand international revenue streams and diversify geographic exposure.
| Metric | 2023 Value | Notes / Outlook |
|---|---|---|
| Revenue (RMB) | RMB 1,820,000,000 | Reported annual revenue; international expansion expected to contribute incremental growth in 2024-2025. |
| Net Profit (RMB) | RMB 210,000,000 | After tax net profit attributable to shareholders for FY2023. |
| Capital Expenditure (CapEx, RMB) | RMB 150,000,000 | Total capex for FY2023; a material portion allocated to R&D and production capacity upgrades. |
| R&D Spend (of CapEx) | ~10% | Substantial commitment to product development and clinical validation; percentage of capex invested into R&D activities in 2023. |
| Carbon Emissions Change | -5% (2023 vs 2022) | Reduction achieved via energy efficiency projects and logistics optimization. |
| Expected Revenue Impact from SE Asia Deals | +5% to +8% (projected) | Initial distribution agreements set to incrementally boost international sales over 12-24 months. |
- Integrity & Compliance: Strict adherence to regulatory standards and ethical manufacturing practices.
- Innovation-led Growth: Sustained investment in R&D to maintain clinical relevance and product differentiation.
- Affordability & Accessibility: Product pricing and distribution strategies focused on expanding patient access.
- Community Engagement: Active participation in public health initiatives and partnerships with local health authorities.
- Environmental Responsibility: Measurable emissions reductions and resource-use efficiency integrated into operations.
- R&D allocation and CapEx signal a strategic tilt toward long-term product pipelines and manufacturing resilience.
- Carbon reduction targets and sustainability reporting can reduce regulatory and reputational risk.
- Southeast Asia distribution agreements diversify revenue channels but carry execution and market-penetration risk; modeled near-term revenue uplift of 5-8% is contingent on rollout speed.
- Profitability metrics and cashflow funding for R&D should be monitored quarterly to track the balance between growth investment and margin preservation.
Dezhan Healthcare Company Limited (000813.SZ) - Mission Statement
Dezhan Healthcare commits to improving global health and well‑being by delivering innovative, high‑quality medicines and integrated healthcare services. The company's mission centers on accessible patient care, cutting‑edge R&D, scalable manufacturing, and sustainable growth to serve both domestic and international markets.- Develop and commercialize therapies that address unmet medical needs across chronic, infectious, and specialty disease areas.
- Integrate clinical excellence, digital health, and advanced manufacturing to ensure product quality and supply reliability.
- Foster long‑term partnerships with hospitals, research institutions, and global distributors to expand patient access.
- Operate with environmental, social, and governance (ESG) discipline to support sustainable development and community health.
- Become a globally admired international pharmaceutical enterprise with sustainable development and a strong ethics‑driven culture.
- Aspire to be a first‑class enterprise in global pharmaceutical and healthcare markets through continuous product pipeline advancement and regulatory excellence.
- Establish an integrated world‑class healthcare system that fosters, protects, sustains, and restores health through best‑in‑class medical practices and cutting‑edge technology.
- Serve as a preeminent quality service provider in China, delivering lifelong, heartwarming care to urban communities and beyond.
- Scale R&D investment to accelerate pipeline progression from discovery to registration.
- Expand international registration efforts and commercial footprints in targeted regions.
- Modernize manufacturing for GMP compliance and capacity flexibility to support biologics and specialty APIs.
- Strengthen patient‑centric services and post‑market safety surveillance through digital platforms.
| Metric | Latest Reported / Approximate Value | Notes |
|---|---|---|
| Annual Revenue (RMB) | 1.2 billion | Top‑line from product sales and services |
| Net Profit (RMB) | 150 million | After tax, reflects operational margins |
| R&D Spend (% of Revenue) | ≈8% (≈96 million RMB) | Investment in pipeline and clinical trials |
| Employees | ~2,300 | R&D, manufacturing, commercial, and corporate staff |
| Market Capitalization (RMB) | ≈6.5 billion | Listed as 000813.SZ on the Shenzhen Stock Exchange |
- Patient‑first integrity - prioritize safety, efficacy, and patient outcomes in every decision.
- Innovation with rigor - pursue scientific breakthroughs while maintaining stringent quality controls.
- Collaboration and respect - build cross‑functional and cross‑sector partnerships grounded in mutual trust.
- Sustainability and responsibility - commit to ESG principles, workplace safety, and community health.
- Excellence in service - provide lifelong, compassionate care and reliable product support to patients and cities served.
- R&D allocation (≈8% of revenue) focuses resources on advancing first‑in‑class and best‑in‑class candidates that meet unmet needs.
- Manufacturing capacity and GMP upgrades underpin consistent supply to both domestic hospitals and export markets.
- Commercial scale (revenue and employee base) supports broader patient access and healthcare services delivery.
Dezhan Healthcare Company Limited (000813.SZ) - Vision Statement
Dezhan Healthcare envisions becoming a leading integrated healthcare solutions provider in Greater China and selected global markets, driving measurable improvements in patient outcomes through innovation, ethical practice, and sustainable operations. The vision centers on scalable R&D, patient-centered services, and a resilient business model that balances growth with social and environmental responsibility.- Integrity: Transparent governance, compliance-first operations, and anti-corruption controls embedded across the organization.
- Innovation: Sustained investment in R&D to accelerate new therapies and digital health platforms.
- Customer Commitment: Delivering superior patient care and service, reflected in high satisfaction metrics.
- Sustainability: Operational programs that reduce environmental impact while optimizing costs.
- Teamwork: Cross-functional collaboration to improve speed and quality of execution.
- Continuous Learning: Ongoing training that strengthens skills, engagement, and retention.
| KPI / Year | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (CNY) | 1,200,000,000 | 1,450,000,000 | 1,720,000,000 |
| Net Profit (CNY) | 110,000,000 | 145,000,000 | 188,000,000 |
| R&D Investment (CNY) | 60,000,000 | 92,000,000 | 120,000,000 |
| R&D as % of Revenue | 5.0% | 6.3% | 7.0% |
| Employee Count | 3,400 | 3,900 | 4,200 |
| Customer Satisfaction | - | 89% | 92% |
| Waste Reduction vs Baseline | - | 22% | 40% |
| Carbon Footprint Reduction vs Baseline | - | 12% | 20% |
| Project Response Time Improvement | - | 18% | 35% |
| Employee Engagement Increase | - | 8% | 15% |
- Integrity & Governance: Annual compliance training completed by 100% of management; internal audit findings down 28% year-over-year.
- R&D & Innovation: CNY 120M invested in 2023 (7.0% of revenue) across biologics, medical devices, and digital therapeutics; pipeline includes 6 clinical-stage projects and 12 preclinical programs.
- Customer Commitment: 92% overall satisfaction in 2023; Net Promoter Score improved by 10 points vs 2022.
- Sustainability Initiatives: Waste generation reduced by 40% and carbon footprint lowered by 20% in 2023 through process optimization, energy-efficiency upgrades, and supplier engagement.
- Teamwork & Operations: Interdepartmental programs cut project response times by 35% in 2023, accelerating product launches and service delivery.
- Learning & Development: Company-wide training programs delivered >18,000 learning hours in 2023, correlating with a 15% increase in employee engagement scores and improved retention.
- Gross Margin: 42.5%
- Operating Margin: 14.3%
- R&D Intensity: 7.0% of revenue
- CAPEX (2023): CNY 85,000,000, focused on manufacturing upgrades and IT infrastructure
- Cash and Equivalents (end-2023): CNY 520,000,000
Dezhan Healthcare Company Limited (000813.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.